Default company panoramic image
Logo

Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics' products treat bacterial AND viral infectious disease through a common mechanism of action in the host.

  • Stage $3M in TTM Revenue
  • Industry Biotechnology
  • Location Atlanta, GA, USA
  • Currency USD
  • Founded September 2008
  • Employees 5
  • Website inhibikase.com

Company Summary

Inhibikase Therapeutics is an innovation engine developing novel strategies for treatment of bacterial and viral infectious disease. Inhibikase Therapeutics’ technology works by inhibiting human pathways used by multiple bacteria and viruses for reproduction in the patient, blocking viral and bacterial reproduction without stimulating resistance. Its products treat respiratory, CNS, liver, kidney and gastrointestinal infections.

Team

  • Default avatar
    Milton H. Werner, PhD
    President & CEO

    Founder, President and CEO of Inhibikase Therapeutics 2008-present. Former Head of Research for Celtaxsys, Inc., a cell migration company rebuilt from loss of technology license to pre-money valuation of $18M in 11 months. Internationally recognized scientist and KOL in cancer, cell biology and infectious disease and former Head of Laboratory at the Rockefeller University leading 25 person team (1995-2007).

  • Default avatar
    Burkhard Blank, MD
    Chief Medical Officer and Executive Vice President

    Former SVP of Drug Medicine and Regulation, Boehringer Ingelheim (Senior Executive Team); Former EVP and CMO Altus Corporation.

  • Default avatar
    Dan Williams
    Controller

    Controller

Advisors

  • Default avatar
    Frank McDaniel, Jonathan Lourie, David Halstead
    Lawyer
    Unconfirmed
    Default avatar
    Ann McCabe
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Milton H. Werner, PhD
    Unconfirmed
    Default avatar
    Coca Werner
    Unconfirmed
    Default avatar
    National Institutes of Health, Department of Defense
    Unconfirmed